Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GBA1 | P04062 | 2/20 | 0.54 |
| ▸ | DTYMK | P23919 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 2/20 | 0.46 |
| ▸ | SKP1 | P63208 | 2/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533854 | 0.84 | GBA1 (0.67) | POLBGBA1KITCKS1BSKP1 | |
| SCHEMBL2801008 | 0.83 | KIT (0.59) | POLBGBA1DTYMKKITTRPA1 | |
| SCHEMBL23107933 | 0.82 | GBA1 (0.58) | POLBGBA1DTYMKKITTRPA1 | |
| SCHEMBL19805095 | 0.81 | DTYMK (0.49) | POLBGBA1DTYMKKITTRPA1 | |
| SCHEMBL17614475 | 0.81 | POLB (0.50) | POLBDTYMKGPR119CNR1CNR2 | |
| SCHEMBL5484112 | 0.80 | GBA1 (0.63) | POLBGBA1KITCKS1BSKP1 | |
| SCHEMBL21196107 | 0.80 | POLB (0.52) | POLBGBA1KITCKS1BSKP1 | |
| SCHEMBL2421627 | 0.80 | TRPA1 (0.68) | POLBTRPA1TRPV1GPR119 | |
| SCHEMBL16908185 | 0.79 | GBA1 (0.60) | POLBGBA1KITCKS1BSKP1 | |
| SCHEMBL16711572 | 0.77 | DTYMK (0.49) | POLBGBA1DTYMKKITCKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-22 | — | — | US | disclosed |
| US-7981881-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981881-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981881-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20040142945-A1 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004043367-A2 | FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | MCL1, FPR1, LTC4S | POLB 3077/4885GBA1 823/4885DTYMK 1314/4885 |
| US-20040142945-A1 | Fused heterocyclic compounds and use thereof | MCL1, NFATC1, BCR | POLB 2935/4885GBA1 506/4885DTYMK 1254/4885 |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | MCL1, FPR1, LTB4R | POLB 3061/4885GBA1 901/4885DTYMK 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.